Treatment of Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas
Poorly differentiated neuroendocrine carcinoma is a rare malignancy that remains a challenge to treat. Poorly differentiated neuroendocrine carcinoma occurs at an incidence of 2% annually in United States. The current standard of care is based largely upon retrospective data. There remains a need for large prospective cooperative group trials in the management of poorly differentiated neuroendocrine carcinoma. In this paper, we will review abstract #e15096 (Paclitaxel, carboplatin, and etoposide (TCE) in advanced poorly differentiated neuroendocrine carcinoma) by Loeffler et al. and #e15071 (Poorly differentiated neuroendocrine carcinoma (NEC G3): prognostic factors and potential novel targets) by Heetfeld et al. presented at the 2013 ASCO Annual Meeting highlighting treatment options in first and second lines for poorly differentiated neuroendocrine carcinoma.
Image: Main gate, Tufts University. Medford, MA, USA. (Author: Daderot; Wikimedia Commons)
Brenner B, Tang LH, Klimstra DS, et al: Small cell carcinomas of the gastrointestinal tract: A review. J Clin Oncol 22:2730-2739, 2004
Van der Gaast A, Verwey J, Prins E, et al: Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer 65:422-424, 1990
Yalan S, Ozsik Y, Tekuzman G: Metastatic small-cell carcinoma of the rectum responding dramatically to combination chemotherapy. Am J Clin Oncol 21:75-76, 1998
Mitry E, Baudin E, Ducreux M, et al: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351-1355, 1999
Fjallskog M, Granberg D, et al: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101-1107, 2001
Hainsworth JD, Gray JR, Stroup SL, et al: Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose intensities. J Clin Oncol 15:3464-3470,1997
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69–76.
Loeffler LM, Mauersberger E, Weimann A, et al. Paclitaxel, carboplatin, and etoposide (TCE) in advanced poorly differentiated neuroendocrine carcinoma. J Clin Oncol 31, 2013 (suppl; abstr #e15096)
Heetfeld M, Kasajima A, Koch A, et al. Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. J Clin Oncol 31, 2013 (suppl; abstr #e15071)
Copyright (c) 2014 Anumeha Gupta, Marvin Duque, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.